If anyone does a comparison to Heartware which is about to list with a low cap you have to wonder what is holding this balloon up.
I mean if the non pulsatile bridge to transplant suspended impeller left ventricle assist device works in both cases why wouldn't you go for the one quarter sized company with the device that attaches to the ventricle and can because it is one third of the size of VCR's device.
Toss in the greater efficiency of not needing a bulky gadget in the abdomen with tubes running up to the jam tart and the fact that the operation time looks like 90minutes instead of 5/8hrs and then the cost and pain and comfort advantage and VCR looks very dear.
Some estimates go to $250k for the VCR bridge to transplant. What a joke. Watch the margins when Heartware and now probably the US giant Guidant run by Johnson and Johnson move in.
I continue to short.
- Forums
- ASX - By Stock
- VCR
- next fall will be to 90 cents
VCR
ventracor limited
next fall will be to 90 cents, page-2
Featured News
Add VCR (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
EQN
EQUINOX RESOURCES LIMITED.
Zac Komur, MD & CEO
Zac Komur
MD & CEO
SPONSORED BY The Market Online